Renaissance Capital logo

Icosavax Priced, Nasdaq: ICVX

Phase 1 biotech developing vaccines for respiratory diseases.

Industry: Health Care

Latest Trade: $26.83 +0.54 (+2.1%)

First Day Return: +133.1%

Return from IPO: +75.3%

Industry: Health Care

We are a biopharmaceutical company leveraging our innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Our VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which we believe will induce broad, robust, and durable protection against the specific viruses targeted. Our pipeline includes vaccine candidates targeting some of the most prevalent viral causes of pneumonia. We are developing these candidates for older adults, a patient population with high unmet need. Our vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). There are currently no vaccines approved for either RSV or hMPV, which are two common causes of pneumonia in older adults. The global market for vaccines was over $50 billion in 2020, of which over $12.5 billion was from vaccines for influenza and pneumococcus, two of the leading causes of pneumonia. Lower respiratory infection, including pneumonia, is the leading cause of death and hospitalization from infections and the fourth highest cause of death globally. Older adults are particularly susceptible to respiratory pathogens and it is estimated that prior to COVID-19, lower respiratory infection caused over one million deaths globally in people over the age of 70 every year.
more less
IPO News for Icosavax
more
IPO Data
IPO File Date 07/07/2021
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 12.1
Deal Size ($mm) $182
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/28/2021
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 12.1
Deal Size ($mm) $182
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Seattle, WA
Founded 2017
Employees 22
Website www.icosavax.com